secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001493152-23-019258
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics receives Nasdaq deficiency notice for late Q1 10-Q filing
----------------------------------------------------------------------------

- Received Nasdaq deficiency on May 23, 2023 for not filing Q1 10-Q on time.
- Failure due to recent auditor change from Plante & Moran to Moss Adams.
- Company has until July 22, 2023 to submit a plan to regain compliance.
- If plan accepted, Nasdaq may grant exception until November 20, 2023.
- Company expects to file Q1 10-Q in coming weeks to resolve delinquency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223019258/0001493152-23-019258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223019258/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer